The purpose of this study is to determine whether NT-proBNP guided treatment of chronic congestive heart failure will reduce heart failure related morbidity and mortality compared to therapy guided by standard clinical judgement.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Universtiy Hospital Maastricht
Maastricht, Limburg, Netherlands
Difference in total number of days alive and outside the hospital between the NT-proBNP guided and the clinical guided group.
Time frame: minimum of one year
All cause mortality
Time frame: at least one year
Cardiovascular mortality
Time frame: at least one year
All cause hospitalization
Time frame: at least one year
Cardiovascular related hospitalization
Time frame: at least one year
Total number of hospitalizations and mortality
Time frame: at least one year
Total number of cardiovascular hospitalizations and mortality
Time frame: at least one year
Differences in primary and secondary outcome measures among renal function and age subgroups
Time frame: At least one year
Differences in evidence based heart failure medication prescription after 3, 6 and 12 months
Time frame: At least one year
Analysis of major endpoints in patients where NT-proBNP levels were at or below the individual target level in at least 75% of all outpatient visits
Time frame: at least one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.